Abbott beats The Street in Q3 on stronger medical device sales
Abbott especially benefitted from the U.S. launch of the next-gen FreeStyle Libre 3 14-day CGM after FDA clearance in May.
Stay updated with breaking news from Style Libre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abbott especially benefitted from the U.S. launch of the next-gen FreeStyle Libre 3 14-day CGM after FDA clearance in May.
FreeStyle Libre system helps reduce acute diabetes-related events, such as severe hypoglycaemia & diabetic ketoacidosis
From digital insoles that correct your walk to bracelets that chart your fertility, wearable health technology is a booming industry.
/PRNewswire/ -- Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living...
/PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute...